Product
Cu 64 anti-CEA monoclonal antibody M5A
1 clinical trial
13 indications
Indication
Breast CancerIndication
Colon CancerIndication
Extrahepatic Bile Duct CancerIndication
Gallbladder CancerIndication
Gastrointestinal CancerIndication
Hepatobiliary CancerIndication
lung cancerIndication
Metastatic CancerIndication
Pancreatic CancerIndication
Rectal CancerIndication
Thyroid Medullary CarcinomaIndication
solid tumorIndication
Protocol SpecificClinical trial
Pilot Study: Detection of Carcinomas Using 64Cu-Labeled M5A Antibody to Carcinoembryonic Antigen (CEA)Status: Active (not recruiting), Estimated PCD: 2022-03-06